Editorial, J Clin Genom Vol: 7 Issue: 1

Pharmacogenomics and Drug Response

Rahul Iyer^*

Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

*Corresponding Author:

Rahul Iyer
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
E-mail: rahul.iyer@jipmer.edu.in

Received: 01-March-2025, Manuscript No. jcg-25-169328; Editor assigned: 4-March-2025, Pre-QC No. jcg-25-169328 (PQ); Reviewed: 20-March-2025, QC No jcg-25-169328; Revised: 26-March-2025, Manuscript No. jcg-25-169328 (R); Published: 30-March-2025, DOI: 10.4172/jcg.1000142

Citation: Rahul I (2025) Pharmacogenomics and Drug Response. J Clin Genom 7:142

Introduction

Pharmacogenomics studies how genetic differences influence drug efficacy and safety. This field allows for personalized drug prescriptions, minimizing adverse drug reactions (ADRs) and enhancing therapeutic efficacy.

Genetic Variants Influencing Drug Metabolism

Genes such as CYP2D6 and TPMT encode drug-metabolizing enzymes with functional polymorphisms [1]. For example, CYP2C9 and VKORC1 genotypes affect warfarin sensitivity [2]. Indian-specific allele frequency data is now available via initiatives like IndiGen, enabling better dose prediction for Indian patients [3].

Clinical Adoption and Case Examples

Pharmacogenomic testing is being adopted in psychiatry (antidepressants), oncology (tamoxifen), and cardiology (clopidogrel) [4]. Tertiary care centers in India have launched pharmacogenomic panels and incorporated them into clinical trials for personalized treatment planning [5].

References

1. Relling MV, Evans WE (2015) Nature.
2. Mega JL (2009) N Engl J Med.
3. (2020) IndiGen Programme Report, CSIR-IGIB.
4. Wilke RA (2007) Annu Rev Genomics Hum Genet.
5. Dunnenberger HM (2015) Am J Health Syst Pharm.